

# Summary of Product Characteristics

## 1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Calciject 40 Solution for Injection

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

### Active Substances

Calcium borogluconate	400.0 mg/ml
(Equivalent to calcium gluconate	332.0 mg/ml)
(Equivalent to calcium	29.6 mg/ml)
Boric Acid	68.0 mg/ml

## 3 PHARMACEUTICAL FORM

Solution for injection.  
A clear pale yellow sterile aqueous solution.

## 4 CLINICAL PARTICULARS

### 4.1 Target Species

Cattle.

### 4.2 Indications for use, specifying the target species

Calciject 40 is indicated in the treatment of hypocalcaemia.

### 4.3 Contraindications

None.

### 4.4 Special warnings for each target species

No special warnings.

### 4.5 Special precautions for use

#### **Special precautions for use in animals**

The solution should be warmed to body temperature before administration. Intravenous injections should be given slowly and stopped at the first signs of adverse reaction. Rapid intravenous injection may result in cardiac arrhythmias and in severely toxæmic animals collapse and death.

As intravenous administration of this product could cause death, this route should only be used by a veterinary surgeon.

**Special precautions to be taken by the person administering the product to animals**

None.

**4.6 Adverse reactions (frequency and seriousness)**

No known undesirable effects.

**4.7 Use during pregnancy, lactation or lay**

Calciject 40 can be safely administered to pregnant and lactating animals.

**4.8 Interaction with other medicinal products and other forms of interactions**

No known interactions.

**4.9 Amounts to be administered and administration route**

Administer by subcutaneous or slow intravenous injection.

Cattle: 150 - 400 ml

**4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Not applicable.

**4.11 Withdrawal period(s)**

Meat: Nil

Milk: Nil

**5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES**

Milk fever which is characterised by hypocalcaemia is caused by an acute drop in the level of ionised calcium. Administration of calcium borogluconate by subcutaneous or slow intravenous injection replenishes plasma calcium levels and reverses the hypocalcaemia.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium Bicarbonate  
Water for Injections

### **6.2 Major incompatibilities**

None known.

### **6.3 Shelf-life**

Shelf life of veterinary medicinal product as packaged for sale: 2 years  
For single use only. Any unused material should be discarded after opening.

### **6.4 Special precautions for storage**

Do not store above 25°C. Protect from light.

### **6.5 Nature and composition of immediate packaging**

400 ml Type III glass vials (amber) sealed with rubber wads (black) and aluminium screw caps, or 400 ml polypropylene containers with bromobutyl bungs (grey) and aluminium caps.

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused product or waste materials should be disposed of in accordance with national requirements.

**7 MARKETING AUTHORISATION HOLDER**

Norbrook Laboratories (Ireland) Limited  
Rossmore Industrial Estate  
Monaghan  
Ireland

**8 MARKETING AUTHORISATION NUMBER(S)**

VPA22664/031/001

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 01 October 1991  
Date of last renewal: 01 October 2006

**10 DATE OF REVISION OF THE TEXT**

February 2019